{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:12:31Z","timestamp":1788581551182,"version":"build-2803163510"},"reference-count":29,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,9,5]]},"DOI":"10.1248\/bpb.b25-00680","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:13:40Z","timestamp":1788560020000},"page":"1438-1443","source":"Crossref","is-referenced-by-count":0,"title":["Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line"],"prefix":"10.1248","volume":"49","author":[{"given":"Keisuke","family":"Okamoto","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics &amp; Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya","family":"Matsui","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics &amp; Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurika","family":"Kikutani","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics &amp; Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinata","family":"Ueda","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics &amp; Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Furugen","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics &amp; Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Narumi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics &amp; Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"},{"name":"Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics &amp; Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"},{"name":"Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060\u20130812, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Stancu C, Sima A. Statins: mechanism of action and effects. <i>J. Cell. Mol. Med.<\/i>, <b>5<\/b>, 378\u2013387 (2001).","DOI":"10.1111\/j.1582-4934.2001.tb00172.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. <i>Lancet<\/i>, <b>366<\/b>, 1267\u20131278 (2005).","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"3","unstructured":"3) Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. <i>Acta Cardiol. Sin.<\/i>, <b>32<\/b>, 631\u2013639 (2016)."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mammen AL. Statin-associated autoimmune myopathy. <i>N. Engl. J. Med.<\/i>, <b>374<\/b>, 664\u2013669 (2016).","DOI":"10.1056\/NEJMra1515161"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sinzinger H, O\u2019Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. <i>Br. J. Clin. Pharmacol.<\/i>, <b>57<\/b>, 525\u2013528 (2004).","DOI":"10.1111\/j.1365-2125.2003.02044.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. <i>Phys. Ther.<\/i>, <b>85<\/b>, 459\u2013465 (2005).","DOI":"10.1093\/ptj\/85.5.459"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. <i>Muscle Nerve<\/i>, <b>42<\/b>, 469\u2013479 (2010).","DOI":"10.1002\/mus.21817"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. <i>Metabolism<\/i>, <b>46<\/b>, 1206\u20131210 (1997).","DOI":"10.1016\/S0026-0495(97)90218-3"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors-simvastatin and pravastatin. <i>Aust. N. Z. J. Med.<\/i>, <b>25<\/b>, 374\u2013375 (1995).","DOI":"10.1111\/j.1445-5994.1995.tb01912.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Steinberg GR, Kemp BE. AMPK in health and disease. <i>Physiol. Rev.<\/i>, <b>89<\/b>, 1025\u20131078 (2009).","DOI":"10.1152\/physrev.00011.2008"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO. Protein kinase C isozymes and the regulation of diverse cell responses. <i>Am. J. Physiol. Lung Cell. Mol. Physiol.<\/i>, <b>279<\/b>, L429\u2013L438 (2000).","DOI":"10.1152\/ajplung.2000.279.3.L429"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Cleland PJ, Appleby GJ, Rattigan S, Clark MG. Exercise-induced translocation of protein kinase C and production of diacylglycerol and phosphatidic acid in rat skeletal muscle <i>in vivo<\/i>: relationship to changes in glucose transport. <i>J. Biol. Chem.<\/i>, <b>264<\/b>, 17704\u201317711 (1989).","DOI":"10.1016\/S0021-9258(19)84628-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kobayashi M, Narumi K, Furugen A, Iseki K. Transport function, regulation, and biology of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4). <i>Pharmacol. Ther.<\/i>, <b>226<\/b>, 107862 (2021).","DOI":"10.1016\/j.pharmthera.2021.107862"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Furugen A, Kobayashi M, Narumi K, Watanabe M, Otake S, Itagaki S, Iseki K. AMP-activated protein kinase regulates the expression of monocarboxylate transporter 4 in skeletal muscle. <i>Life Sci.<\/i>, <b>88<\/b>, 163\u2013168 (2011).","DOI":"10.1016\/j.lfs.2010.11.003"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Narumi K, Kobayashi M, Otake S, Furugen A, Takahashi N, Ogura J, Itagaki S, Hirano T, Yamaguchi H, Iseki K. Regulation of human monocarboxylate transporter 4 in skeletal muscle cells: the role of protein kinase C (PKC). <i>Int. J. Pharm.<\/i>, <b>428<\/b>, 25\u201332 (2012).","DOI":"10.1016\/j.ijpharm.2012.02.021"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kikutani Y, Kobayashi M, Konishi T, Sasaki S, Narumi K, Furugen A, Takahashi N, Iseki K. Involvement of monocarboxylate transporter 4 expression in statin-induced cytotoxicity. <i>J. Pharm. Sci.<\/i>, <b>105<\/b>, 1544\u20131549 (2016).","DOI":"10.1016\/j.xphs.2016.01.014"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nishimoto T, Tozawa R, Amano Y, Wada T, Imura Y, Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. <i>Biochem. Pharmacol.<\/i>, <b>66<\/b>, 2133\u20132139 (2003).","DOI":"10.1016\/j.bcp.2003.08.011"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kobayashi M, Chisaki I, Narumi K, Hidaka K, Kagawa T, Itagaki S, Hirano T, Iseki K. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. <i>Life Sci.<\/i>, <b>82<\/b>, 969\u2013975 (2008).","DOI":"10.1016\/j.lfs.2008.02.019"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Okamoto K, Kitaichi F, Saito Y, Ueda H, Narumi K, Furugen A, Kobayashi M. Antioxidant effect of ascorbic acid against cisplatin-induced nephrotoxicity and P-glycoprotein expression in rats. <i>Eur. J. Pharmacol.<\/i>, <b>909<\/b>, 174395 (2021).","DOI":"10.1016\/j.ejphar.2021.174395"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Okamoto K, Takizawa J, Ueda H, Narumi K, Kobayashi M. Effect of acid suppressants on adverse events of immune checkpoint inhibitors using real-world databases. <i>Anticancer Res.<\/i>, <b>45<\/b>, 3287\u20133293 (2025).","DOI":"10.21873\/anticanres.17689"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. <i>Expert Opin. Investig. Drugs<\/i>, <b>10<\/b>, 2117\u20132140 (2001).","DOI":"10.1517\/13543784.10.12.2117"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Lee J-W, Park JA, Kim S-H, Seo JH, Lim K-J, Jeong J-W, Jeong C-H, Chun K-H, Lee S-K, Kwon Y-G, Kim K-W. Protein kinase C-delta regulates the stability of hypoxia-inducible factor-1 alpha under hypoxia. <i>Cancer Sci.<\/i>, <b>98<\/b>, 1476\u20131481 (2007).","DOI":"10.1111\/j.1349-7006.2007.00535.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Sassano A, Altman JK, Gordon LI, Platanias LC. Statin-dependent activation of protein kinase C\u03b4 in acute promyelocytic leukemia cells and induction of leukemic cell differentiation. <i>Leuk. Lymphoma<\/i>, <b>53<\/b>, 1779\u20131784 (2012).","DOI":"10.3109\/10428194.2012.668287"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Saraiva L, Fresco P, Pinto E, Gon\u00e7alves J. Isoform-selectivity of PKC inhibitors acting at the regulatory and catalytic domain of mammalian PKC-alpha, -betaI, -delta, -eta and -zeta. <i>J. Enzyme Inhib. Med. Chem.<\/i>, <b>18<\/b>, 475\u2013483 (2003).","DOI":"10.1080\/14756360310001603158"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Saxena A, Scaini G, Bavaresco DV, Leite C, Valvassori SS, Carvalho AF, Quevedo J. Role of protein kinase C in bipolar disorder: a review of the current literature. <i>Complex Psychiatry<\/i>, <b>3<\/b>, 108\u2013124 (2017).","DOI":"10.1159\/000480349"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Richter EA, Derave W, Wojtaszewski JF. Glucose, exercise and insulin: emerging concepts. <i>J. Physiol.<\/i>, <b>535<\/b>, 313\u2013322 (2001).","DOI":"10.1111\/j.1469-7793.2001.t01-2-00313.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Brodie C, Blumberg PM. Regulation of cell apoptosis by protein kinase C delta. <i>Apoptosis<\/i>, <b>8<\/b>, 19\u201327 (2003).","DOI":"10.1023\/A:1021640817208"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Wilson MC, Jackson VN, Heddle C, Price NT, Pilegaard H, Juel C, Bonen A, Montgomery I, Hutter OF, Halestrap AP. Lactic acid efflux from white skeletal muscle is catalyzed by the monocarboxylate transporter isoform MCT3. <i>J. Biol. Chem.<\/i>, <b>273<\/b>, 15920\u201315926 (1998).","DOI":"10.1074\/jbc.273.26.15920"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. <i>Toxicol. Pathol.<\/i>, <b>33<\/b>, 246\u2013257 (2005).","DOI":"10.1080\/01926230590908213"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b25-00680\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:27:37Z","timestamp":1788578857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b25-00680\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00680","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"article-number":"b25-00680"}}